University of Maryland
, College Park researchers have received a US$4.1 million National Institutes of Health
contract to continue research on a vaccine that, in early trials, successfully immunised monkeys against SARS and human parainfluenza viruses.
The scientists, at the Virginia-Maryland Regional College of Veterinary Medicine (VMRCVM), engineered a recombinant Newcastle Disease virus
(NDV), an avian paramyxovirus
, to create a vaccine that holds promise to protect humans against multiple diseases.
“The Newcastle Disease virus makes a very good vector for creating human vaccines,” says Siba Samal, the research team leader and associate dean of the VMRCVM at Maryland. “NDV replicates in species other than poultry, but not enough to cause disease. Also, there are nine types of paramyxoviruses and NDV is Serotype 1, so we can make similar vaccine vectors with other avian paramyxovirus types, which can be used to protect against more than one disease.”
Their future research will include a vaccine for the avian influenza
H5N1 and other human viruses for which vaccines are currently not available.